A.P. Pereverzev, O.D. Ostroumova, O.N. TkachevaPirogov Russian National Research Medical University, Russian Clinical and Research Center of Gerontology, Moscow, Russia
Type 2 diabetes mellitus (DM2) is a metabolic disease that develops as a result of insulin secretion dysfunction or reduced tissue sensitivity to insulin action (insulin resistance). DM2 patients often suffer not only from the symptoms of elevated blood glucose levels, but also from the manifestations and complications of comorbidities that dictate the need for prescribing drug therapy. As a result, diabetic patients have a high risk of polypragmasy, which can cause a serious complication - hypoglycemia. The article provides a brief overview of some pharmacokinetic and pharmacodynamic interactions of glucose-lowering drugs, including with food and biologically active supplements.
For citations: Pereverzev A.P., Ostroumova O.D., Tkacheva O.N. Potential drug interactions of oral hypoglycemic drugs that increase the risk of hypoglycemia. Farmateka. 2019;26(4):96–99. (in Russian). DOI: https://dx.doi.org/10.18565/pharmateca.2019.4.96-99
Corresponding author: Olga D. Ostroumova, MD, Professor, member of the Russian Association of Gerontologists and Geriatricians (RAGG), Pirogov Russian National Research Medical University, Russian Clinical and Research Center of Gerontology, Moscow, Russia; e-mail: email@example.com
Address: 16, 1-st Leonov Street, Moscow 129226, Russian Federation